Evaluating immune-related adverse events associated with the novel lymphocyte activation gene 3 inhibitor relatlimab in combination treatment of malignant melanoma: A retrospective comparative pharmacovigilance analysis of the Food and Drug Administration adverse events reporting system database.

Evaluating immune-related adverse events associated with the novel lymphocyte activation gene 3 inhibitor relatlimab in combination treatment of malignant melanoma: A retrospective comparative pharmacovigilance analysis of the Food and Drug Administration adverse events reporting system database. — SciRadar